Anti-laminin γ1 pemphigoid accompanied by autoantibodies to laminin α3 and γ2 subunits of laminin-332.

INTRODUCTION

Low-Penetrance Copy Number Variants (LP-CNVs) are well-known to contribute to neurodevelopmental disorders and are also found in healthy individuals, presenting significant challenges to genetic counselling. However, data on the clinical management of LP-CNVs in Portugal is lacking.

METHODS

An online questionnaire was administered to Clinical Geneticists in Portugal regarding their management of LP-CNV and ethical issues were addressed.

RESULTS

The results showed a significant absence of agreement on LP-CNVs disclosure, particularly concerning whether decisions should be guided by expert panels or individualized for each case. Clinicians acknowledged the substantial challenges patients and families face in understanding genetic information, highlighting the need for a shared decision-making approach. Furthermore, there was considerable variability in ethical perspectives regarding prenatal diagnosis and preimplantation genetic testing for LP-CNVs, emphasizing the need for clear guidelines. Our results strongly advocate for the development of national guidelines mirroring those established in other countries.

DISCUSSION: This work underscores several complex ethical issues requiring urgent exploration internationally. The observed postcode lottery highlights a failure of distributive justice, necessitating equitable access to standardized genomic knowledge across healthcare regions. Furthermore, the uncertainty challenge renders traditional non-directive counseling increasingly unsustainable, requiring a shift toward Shared Decision-Making (SDM) to balance child welfare against parental autonomy in navigating genomic ambiguity.